Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nucletron Kuske Template Reduces Breast Brachytherapy Treatment Time

This article was originally published in The Gray Sheet

Executive Summary

Nucletron will use a recently released ten-year study of its Kuske Breast Templateto promote its interstitial accelerated partial breast irradiation (APBI) system

You may also be interested in...



Cytyc Pays 10-Times Sales For Proxima, Breast Cancer Therapy Market Entry

Cytyc likely will divest Proxima Therapeutics' GliaSite brain tumor radiation therapy system after acquiring the company for its MammoSite breast cancer system under a $160 mil. deal Feb. 9

Cytyc Pays 10-Times Sales For Proxima, Breast Cancer Therapy Market Entry

Cytyc likely will divest Proxima Therapeutics' GliaSite brain tumor radiation therapy system after acquiring the company for its MammoSite breast cancer system under a $160 mil. deal Feb. 9

Proxima MammoSite RTS For Early-Stage Breast Cancer To Launch By May 17

Proxima Therapeutics will emphasize its single-catheter MammoSite radiation therapy system's ease of use over multi-catheter competitor devices in treating early-stage breast cancer

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel